| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 4. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | levodopa/carbidopa (Numient®) |
| Formulation | 95 mg/23.75 mg, 145 mg/36.25 mg, 195 mg/48.75 mg and 245 mg/61.25 mg modified-release capsule |
| Reference number | 1296 |
| Indication | Symptomatic treatment of adult patients with Parkinson's disease |
| Company | Impax Laboratories, Inc |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 03/12/2015 |